This Article supports SDG 3 by showing that an HCV testing (point-of-care) and treatment programme implemented in users of a supervised drug cosumption service in Canada was beneficial, with a large degree of positive testing, testing acceptance, and treatment engagement. The study suggests that on-site point of care testing and treatment for HCV in supervised consumption services is effective in reaching this population
This Article supports SDG 3 by using modelling to estimate the impact of immigration on hepatitis B prevalence in the USA, in order to more accurately assess the hepatitis B burden, which might not be accurately measured by national serosurveys. The study found a significantly higher burden of hepatitis B (1.8 million cases), significantly higher than that found in national serosurveys.
This Article supports SDG 3 by assessing the incidence of HIV and HCV infection among people who inject drugs, a population at higher risk of these infections. In this systematic review, HCV estimates came from studies in 24 countries. Pooled HCV incidence was 12.1 per 100 person-years; data for both infections were scarce, suggesting increased efforts are needed to keep track of these infections in this population.
This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
This Article supports Sustainable Development Goal 3 by estimating the proportion of dementia attributable to hypertension, finding an overall global population attributable fraction of 15.8%. Results were also broken down by region and age. The authors note that the estimates from this study could help to inform public health policy at global and national levels.
This Article supports Sustainable Development Goal 3 by describing a cohort characterization model for Alzheimer’s Disease built on medications and diagnoses data that are widely available in a structured format in electronic health records (EHRs), showing that standard machine learning applied to sequences of EHR data can produce scalable computational characterization of Alzheimer’s disease cohorts.
This Article supports Sustainable Development Goal 3 by highlighting differential effects of sleep disturbances on resting-state neural activity in patients on the Alzheimer's disease spectrum relative to healthy adults, suggesting a key role of sleep disturbances in the neurophysiological changes seen in Alzheimer's disease, with implications for basic research and clinical intervention.
The authors explore automatic and early detection methods for Alzheimer’s disease (AD) using deep learning techniques in order to improve the speed and accessibility of current testing methods. They propose a deep transfer learning model as a new approach for accurately detecting categories of Alzheimer's disease. The research serves SDG 3's aim in highlighing and seeking better treatment for AD, an increasingly serious global public health issue.
This is a Personal View discussing socioeconomic risk factors for dementia in women in Latin American Countries, with emphasis on gender roles and expectations that can infleuence the onset and prevalence of dementia
In this study, a novel reporter substrate named C8CF3-coumarin was synthesized and then characterized, an assay protocol was developed to identify small molecular activators of PLCγ enzymes, and a proof-of-principle high throughput screen was conducted using PLCγ2 and the LOPAC1280 library. These studies showed that C8CF3-coumarin could indeed monitor PLCγ enzyme activity and identify potential small molecule activators from a screen. The identification of such small molecule PLCγ2 activators would be of great utility to the Alzheimer's disease research community by serving as both chemical probes to study the modulation of PLCγ2 and as potential therapeutic agents.